Emergency Department-Initiated Medications for Alcohol Use Disorder

Description

The proposed study will be the first randomized clinical trial to evaluate a comprehensive Emergency Department (ED)-based intervention for moderate to severe Alcohol Use Disorder (AUD) combining Screening, Brief Intervention and Referral to Treatment (SBIRT) with ED-initiated medications for treatment of alcohol use disorder (MAUD). The primary objective of this phase 3 study is to evaluate for differences in treatment engagement 30 days after ED visit between emergency department patients with moderate to severe alcohol use disorder (AUD) who are randomized to initiate medications for the treatment for AUD in the ED in addition to receiving a brief intervention and referral to ongoing treatment, which all participants will receive. The secondary objective of this study is to evaluate the difference in reduction of heavy drinking days between the two ED treatment models during the 30 days post ED visit.

Conditions

Alcohol Use Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

The proposed study will be the first randomized clinical trial to evaluate a comprehensive Emergency Department (ED)-based intervention for moderate to severe Alcohol Use Disorder (AUD) combining Screening, Brief Intervention and Referral to Treatment (SBIRT) with ED-initiated medications for treatment of alcohol use disorder (MAUD). The primary objective of this phase 3 study is to evaluate for differences in treatment engagement 30 days after ED visit between emergency department patients with moderate to severe alcohol use disorder (AUD) who are randomized to initiate medications for the treatment for AUD in the ED in addition to receiving a brief intervention and referral to ongoing treatment, which all participants will receive. The secondary objective of this study is to evaluate the difference in reduction of heavy drinking days between the two ED treatment models during the 30 days post ED visit.

Emergency Department-Initiated Medications for Alcohol Use Disorder

Emergency Department-Initiated Medications for Alcohol Use Disorder

Condition
Alcohol Use Disorder
Intervention / Treatment

-

Contacts and Locations

New Haven

Yale New Haven Hospital, New Haven, Connecticut, United States, 06520

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Between 18 and 80 years in age
  • 2. Diagnosed with moderate to severe Alcohol Use Disorder
  • 3. Stated willingness and ability to comply with all study procedures and availability for the duration of the study
  • 4. Reproductive aged females will have a negative pregnancy test within the past 24 hours and agree to use of highly effective family planning during study participation period
  • 5. Able to speak English sufficiently to understand study procedures and provide written informed consent to participate in the study.
  • 6. Clinical Alcohol Withdrawal Scale (CIWA-Ar) ≥ 4.
  • 1. A current diagnosis of OUD, self-reported past 7 day opioid or opioid pain medication use, or a positive urine opioid screen (opiates, methadone, buprenorphine, oxycodone, hydrocodone, tramadol and fentanyl)
  • 2. Current prescription of opioid pain medications, or anticipated need for opioid pain medications during the study period (i.e. planned surgery)
  • 3. History of complicated alcohol withdrawal
  • 4. Condition that precludes interview (i.e., life threatening injury/illness)
  • 5. Inability to consent due to cognitive impairment
  • 6. Awaiting an acute psychiatric evaluation for psychosis or suicidal ideation
  • 7. In police custody
  • 8. Unable to provide contact information
  • 9. Previously enrolled in this study or currently enrolled in another study for which they are currently receiving study medications or active ongoing intervention
  • 10. Any contraindication to naltrexone or gabapentin, including known allergy, renal failure, acute hepatitis, hepatic failure,1 or severe lung disease or other chronic conditions such as chronic obstructive pulmonary disease (COPD).
  • 11. Creatine Clearance \<60 mL/min within past 72 hours.
  • 12. Currently pregnant or breast feeding
  • 13. Requiring hospitalization at the time of the index visit
  • 14. Past week treatment with medications for the treatment of alcohol use disorder
  • 15. Taking gabapentin or naltrexone for any reason
  • 16. Appearing unable or unwilling to comply with discharge instructions or complete follow-up
  • 17. Current residence outside of the state of Connecticut

Ages Eligible for Study

18 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Yale University,

Kathryn Hawk, MD, MHS, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

2028-03-01